Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Vista sencilla de ítem
dc.creatorPoh, Chek Meng
dc.creatorCarissimo, Guillaume
dc.creatorWang, Bei
dc.creatorAmrun, Siti Naqiah
dc.creatorLee, Cheryl Yi Pin
dc.creatorChee, Rhonda Sin Ling
dc.creatorFong, Siew Wai
dc.creatorYeo, Nicholas Kim Wah
dc.creatorLee, Wen Hsin
dc.creatorTorres-Ruesta, Anthony
dc.creatorLeo, Yee Sin
dc.creatorChen, Mark I.Cheng
dc.creatorTan, Seow Yen
dc.creatorChai, Louis Yi Ann
dc.creatorKalimuddin, Shirin
dc.creatorKheng, Shirley Seah Gek
dc.creatorThien, Siew Yee
dc.creatorYoung, Barnaby Edward
dc.creatorLye, David C.
dc.creatorHanson, Brendon John
dc.creatorWang, Cheng I.
dc.creatorRenia, Laurent
dc.creatorNg, Lisa F.P.
dc.date.accessioned2020-07-22T22:02:27Z
dc.date.available2020-07-22T22:02:27Z
dc.date.created2020-06-01
dc.description.abstractenglishGiven the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.spa
dc.format.extent7 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41467-020-16638-2spa
dc.identifier.issn2041-1723spa
dc.identifier.otherhttps://www.nature.com/articles/s41467-020-16638-2spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10996
dc.publisherScience Directeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectAnticuerpos neutralizantesspa
dc.subject.keywordNeutralising antibodiesspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleTwo linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patientsspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
s41467-020-16638-2.pdf
Tamaño:
1.06 MB
Formato:
Adobe Portable Document Format
Descripción:
Ver documento
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS